Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anastrozole + eribulin
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of anastrozole, a non-steroidal aromatase inhibitor, and eribulin, a microtubule inhibitor. Anastrozole works by reducing estrogen production in postmenopausal women by inhibiting the aromatase enzyme, while eribulin inhibits the growth phase of microtubules without affecting the shortening phase, leading to G2/M cell-cycle block, disruption of mitotic spindles, and ultimately apoptotic cell death. This combination targets both hormonal and cell division pathways in breast cancer treatment.
02
Targets
CYP19A1 (Aromatase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on anastrozole + eribulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anastrozole + eribulin.